-
1.
Kidney International Supplements. Chapter 4: Steroid-resistant nephrotic syndrome in children. Kidney Int Suppl. 2012;2(2):172-6. doi: 10.1038/kisup.2012.17. [PubMed: 25018929]. [PubMed Central: PMC4089623].
-
2.
Shankland SJ, Smeets B, Pippin JW, Moeller MJ. The emergence of the glomerular parietal epithelial cell. Nat Rev Nephrol. 2014;10(3):158-73. doi: 10.1038/nrneph.2014.1. [PubMed: 24468766].
-
3.
Zeier M, Reiser J. suPAR and chronic kidney disease-A podocyte story. Pflugers Arch. 2017;469(7-8):1017-20. doi: 10.1007/s00424-017-2026-7. [PubMed: 28689240].
-
4.
Dande RR, Peev V, Altintas MM, Reiser J. Soluble urokinase receptor and the kidney response in diabetes mellitus. J Diabetes Res. 2017;2017:3232848. doi: 10.1155/2017/3232848. [PubMed: 28596971]. [PubMed Central: PMC5449757].
-
5.
Wetzels JF. Cyclophosphamide-induced gonadal toxicity: A treatment dilemma in patients with lupus nephritis? Neth J Med. 2004;62(10):347-52. [PubMed: 15683089].
-
6.
Lin W, Li HY, Lin S, Zhou T. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: A meta-analysis. Drug Des Devel Ther. 2019;13:2179-86. doi: 10.2147/DDDT.S209211. [PubMed: 31308629]. [PubMed Central: PMC6613398].
-
7.
Zhu LB, Liu LL, Yao L, Wang LN. Efficacy and safety of tacrolimus versus cyclophosphamide for primary membranous nephropathy: A meta-analysis. Drugs. 2017;77(2):187-99. doi: 10.1007/s40265-016-0683-z. [PubMed: 28084563].
-
8.
Li YC, Huang J, Li X, Zhao SM. A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis. Nefrologia. 2019;39(3):269-76. doi: 10.1016/j.nefro.2018.10.008. [PubMed: 30755327].
-
9.
Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 2012;82(10):1130-5. doi: 10.1038/ki.2012.238. [PubMed: 22763815].
-
10.
Li HY, Zhang X, Zhou T, Zhong Z, Zhong H. Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis. BMC Nephrol. 2019;20(1):384. doi: 10.1186/s12882-019-1575-8. [PubMed: 31646979]. [PubMed Central: PMC6813125].
-
11.
Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27(3):157-72. doi: 10.3233/DMA-2009-0657. [PubMed: 19893210]. [PubMed Central: PMC3835059].
-
12.
Godtfredsen NS, Jorgensen DV, Marsaa K, Ulrik CS, Andersen O, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD. Respir Res. 2018;19(1):97. doi: 10.1186/s12931-018-0803-2. [PubMed: 29783959]. [PubMed Central: PMC5963104].
-
13.
Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373(20):1916-25. doi: 10.1056/NEJMoa1506362. [PubMed: 26539835]. [PubMed Central: PMC4701036].
-
14.
Winnicki W, Sunder-Plassmann G, Sengolge G, Handisurya A, Herkner H, Kornauth C, et al. Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis and impact of detection method. Sci Rep. 2019;9(1):13783. doi: 10.1038/s41598-019-50405-8. [PubMed: 31551522]. [PubMed Central: PMC6760112].
-
15.
Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS, et al. Soluble urokinase receptor and acute kidney injury. N Engl J Med. 2020;382(5):416-26. doi: 10.1056/NEJMoa1911481. [PubMed: 31995687]. [PubMed Central: PMC7065830].
-
16.
Hahm E, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat Med. 2017;23(1):100-6. doi: 10.1038/nm.4242. [PubMed: 27941791]. [PubMed Central: PMC5405698].
-
17.
Yonata A, Effendi I, Ali Z, Suhaimi N, Suprapti S. The role of soluble urokinase-type plasminogen activator receptor (suPAR) in chronic kidney disease. Indones J Kidney Hypertension. 2018;1(1):18-21. doi: 10.32867/inakidney.2018.010103.
-
18.
Schulz CA, Persson M, Christensson A, Hindy G, Almgren P, Nilsson PM, et al. Soluble urokinase-type plasminogen activator receptor (suPAR) and impaired kidney function in the population-based malmo diet and cancer study. Kidney Int Rep. 2017;2(2):239-47. doi: 10.1016/j.ekir.2016.11.004. [PubMed: 28367534]. [PubMed Central: PMC5362148].
-
19.
Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12(3):502-17. doi: 10.2215/CJN.05960616. [PubMed: 28242845]. [PubMed Central: PMC5338705].
-
20.
Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, Tracy M, et al. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab. BMC Nephrol. 2018;19(1):361. doi: 10.1186/s12882-018-1177-x. [PubMed: 30558559]. [PubMed Central: PMC6296111].
-
21.
Saleem MA. What is the role of soluble urokinase-type plasminogen activator in renal disease? Nephron. 2018;139(4):334-41. doi: 10.1159/000490118. [PubMed: 29909410].
-
22.
Shuai T, Pei Jing Y, Huang Q, Xiong H, Liu J, Zhu L, et al. Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: A systematic review and meta-analysis. BMJ Open. 2019;9(10). e031812. doi: 10.1136/bmjopen-2019-031812. [PubMed: 31594897]. [PubMed Central: PMC6797292].
-
23.
Mousa SO, Saleh SM, Aly HM, Amin MH. Evaluation of serum soluble urokinase plasminogen activator receptor as a marker for steroid-responsiveness in children with primary nephrotic syndrome. Saudi J Kidney Dis Transpl. 2018;29(2):290-6. doi: 10.4103/1319-2442.229266. [PubMed: 29657195].
-
24.
Stone H, Magella B, Bennett MR. The search for biomarkers to aid in diagnosis, differentiation, and prognosis of childhood idiopathic nephrotic syndrome. Front Pediatr. 2019;7:404. doi: 10.3389/fped.2019.00404. [PubMed: 31681707]. [PubMed Central: PMC6805718].
-
25.
Wada T, Nangaku M. A circulating permeability factor in focal segmental glomerulosclerosis: The hunt continues. Clin Kidney J. 2015;8(6):708-15. doi: 10.1093/ckj/sfv090. [PubMed: 26613029]. [PubMed Central: PMC4655796].
-
26.
Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012;23(12):2051-9. doi: 10.1681/ASN.2012030302. [PubMed: 23138488]. [PubMed Central: PMC3507361].
-
27.
Lee JM, Yang JW, Kronbichler A, Eisenhut M, Kim G, Lee KH, et al. Increased serum soluble urokinase-type plasminogen activator receptor (suPAR) levels in FSGS: A meta-analysis. J Immunol Res. 2019;2019:5679518. doi: 10.1155/2019/5679518. [PubMed: 31089477]. [PubMed Central: PMC6476117].
-
28.
Peng Z, Mao J, Chen X, Cai F, Gu W, Fu H, et al. Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children. Pediatr Nephrol. 2015;30(2):301-7. doi: 10.1007/s00467-014-2892-6. [PubMed: 25034499].
-
29.
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952-60. doi: 10.1038/nm.2411. [PubMed: 21804539]. [PubMed Central: PMC4089394].
-
30.
Sun P, Yu L, Huang J, Wang S, Zou W, Yang L, et al. Soluble urokinase receptor levels in secondary focal segmental glomerulosclerosis. Kidney Dis. 2019;5(4):239-46. doi: 10.1159/000497353. [PubMed: 31768381]. [PubMed Central: PMC6873037].
-
31.
Theilade S, Lyngbaek S, Hansen TW, Eugen-Olsen J, Fenger M, Rossing P, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med. 2015;277(3):362-71. doi: 10.1111/joim.12269. [PubMed: 24830873].
-
32.
Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015;26(1):133-47. doi: 10.1681/ASN.2013111213. [PubMed: 24925721]. [PubMed Central: PMC4279736].
-
33.
de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004;24(1):13-39. doi: 10.1002/med.10054. [PubMed: 14595671].
-
34.
Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: A systematic review. Intensive Care Med. 2012;38(9):1418-28. doi: 10.1007/s00134-012-2613-1. [PubMed: 22706919]. [PubMed Central: PMC3423568].
-
35.
Borne Y, Persson M, Melander O, Smith JG, Engstrom G. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail. 2014;16(4):377-83. doi: 10.1002/ejhf.49. [PubMed: 24464777].
-
36.
Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268(3):296-308. doi: 10.1111/j.1365-2796.2010.02252.x. [PubMed: 20561148].
-
37.
Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. 2012;222(1):8-14. doi: 10.1016/j.atherosclerosis.2011.10.044. [PubMed: 22137664].
-
38.
Lyngbaek S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol. 2013;167(6):2904-11. doi: 10.1016/j.ijcard.2012.07.018. [PubMed: 22909410].
-
39.
Eapen DJ, Manocha P, Ghasemzadeh N, Patel RS, Al Kassem H, Hammadah M, et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc. 2014;3(5). e001118. doi: 10.1161/JAHA.114.001118. [PubMed: 25341887]. [PubMed Central: PMC4323820].
-
40.
Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14(1):55-63. doi: 10.1038/nm1696. [PubMed: 18084301].
-
41.
D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398-411. doi: 10.1056/NEJMra1106556. [PubMed: 22187987].
-
42.
Reidy K, Kaskel FJ. Pathophysiology of focal segmental glomerulosclerosis. Pediatr Nephrol. 2007;22(3):350-4. doi: 10.1007/s00467-006-0357-2. [PubMed: 17216262]. [PubMed Central: PMC1794138].
-
43.
Akhavan S. M, Farahani N, Razavi MR, Heydari H, Arsang-Jang S. Rituximab versus cyclophosphamide for the treatment of children with steroid resistance nephrotic syndrome; A clinical trial study. Immunopathologia Persa. 2019;5(2):e15. doi: 10.15171/ipp.2019.15.
-
44.
Au WY, Lie AK, Lam CC, Fan ST, Liu CL, Young K, et al. Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mismatched second liver transplantation: salvage with plasmapheresis and prostacyclin. Haematologica. 2000;85(6):659-62. [PubMed: 10870125].
-
45.
Pham PT, Peng A, Wilkinson AH, Gritsch HA, Lassman C, Pham PC, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis. 2000;36(4):844-50. doi: 10.1053/ajkd.2000.17690. [PubMed: 11007689].
-
46.
Yenigun EC, Turgut D, Piskinpasa S, Ozturk R, Dede F, Odabas AR. Cyclosporine is not inferior to cyclophosphamide in the treatment of idiopathic membranous glomerulonephritis: Single centre experience. Int J Clin Exp Med. 2016;1:316-22.
-
47.
Chen S, Ren S, Wang AY, Tran H, Li Z, Cheng X, et al. Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: Protocol of a multicenter, randomized, controlled, open study. Trials. 2020;21(1):219. doi: 10.1186/s13063-020-4144-3. [PubMed: 32093742]. [PubMed Central: PMC7041116].
-
48.
Rezakhaniha B, Arianpour N, Siroosbakhat S. Efficacy of desmopressin in treatment of nocturia in elderly men. J Res Med Sci. 2011;16(4):516-23. [PubMed: 22091268]. [PubMed Central: PMC3214357].
-
49.
Thompson A, Cattran DC, Blank M, Nachman PH. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol. 2015;26(12):2930-7. doi: 10.1681/ASN.2015010091. [PubMed: 26078365]. [PubMed Central: PMC4657845].
-
50.
Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697-704. doi: 10.1681/ASN.2009080861. [PubMed: 20110379]. [PubMed Central: PMC2844306].
-
51.
Kim J, Patnaik N, Chorny N, Frank R, Infante L, Sethna C. Second-line immunosuppressive treatment of childhood nephrotic syndrome: A single-center experience. Nephron Extra. 2014;4(1):8-17. doi: 10.1159/000357355. [PubMed: 24575119]. [PubMed Central: PMC3934602].
-
52.
Ren H, Shen P, Li X, Pan X, Zhang W, Chen N. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: A randomized controlled trial. Am J Nephrol. 2013;37(1):84-90. doi: 10.1159/000346256. [PubMed: 23343906].
-
53.
Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. Kidney Int. 2017;92(1):248-57. doi: 10.1016/j.kint.2017.01.019. [PubMed: 28318625].
-
54.
Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int. 2014;85(3):649-58. doi: 10.1038/ki.2013.546. [PubMed: 24429405].
-
55.
Zagury A, Oliveira AL, Montalvao JA, Novaes RH, Sa VM, Moraes CA, et al. Steroid-resistant idiopathic nephrotic syndrome in children: Long-term follow-up and risk factors for end-stage renal disease. J Bras Nefrol. 2013;35(3):191-9. doi: 10.5935/0101-2800.20130031. [PubMed: 24100738].
-
56.
Lim BJ, Yang JW, Do WS, Fogo AB. Pathogenesis of focal segmental glomerulosclerosis. J Pathol Transl Med. 2016;50(6):405-10. doi: 10.4132/jptm.2016.09.21. [PubMed: 27744657]. [PubMed Central: PMC5122732].
-
57.
Hjorten R, Anwar Z, Reidy KJ. Long-term outcomes of childhood onset nephrotic syndrome. Front Pediatr. 2016;4:53. doi: 10.3389/fped.2016.00053. [PubMed: 27252935]. [PubMed Central: PMC4879783].
-
58.
Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol. 2015;11(2):76-87. doi: 10.1038/nrneph.2014.216. [PubMed: 25447132]. [PubMed Central: PMC4772430].
-
59.
Soltysiak J, Zachwieja J, Benedyk A, Lewandowska-Stachowiak M, Nowicki M, Ostalska-Nowicka D. Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis. Minerva Pediatr. 2019;71(1):4-11. doi: 10.23736/S0026-4946.16.04461-3. [PubMed: 27070416].
-
60.
Savin VJ, McCarthy ET, Sharma M. Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis. Kidney Res Clin Pract. 2012;31(4):205-13. doi: 10.1016/j.krcp.2012.10.002. [PubMed: 26889423]. [PubMed Central: PMC4716100].
-
61.
Roca N, Jatem E, Martin ML, Munoz M, Molina M, Martinez C, et al. Relationship between soluble urokinase-type plasminogen activator receptor and serum biomarkers of endothelial activation in patients with idiopathic nephrotic syndrome. Clin Kidney J. 2021;14(2):543-9. doi: 10.1093/ckj/sfz173. [PubMed: 33623677]. [PubMed Central: PMC7886542].
-
62.
Cara-Fuentes G, Araya C, Wei C, Rivard C, Ishimoto T, Reiser J, et al. CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation. Nefrologia. 2013;33(5):727-31. doi: 10.3265/Nefrologia.pre2013.Jun.12085. [PubMed: 24089165].
-
63.
Zhao Y, Liu L, Huang J, Shi S, Lv J, Liu G, et al. Plasma soluble urokinase receptor level is correlated with podocytes damage in patients with IgA nephropathy. PLoS One. 2015;10(7). e0132869. doi: 10.1371/journal.pone.0132869. [PubMed: 26167688]. [PubMed Central: PMC4500560].
-
64.
Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, et al. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med. 2014;12:81. doi: 10.1186/1741-7015-12-81. [PubMed: 24884842]. [PubMed Central: PMC4064821].
-
65.
Enocsson H, Wettero J, Skogh T, Sjowall C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transl Res. 2013;162(5):287-96. doi: 10.1016/j.trsl.2013.07.003. [PubMed: 23916811].
-
66.
Zaitoon YA, Shehab AA, Mohamed NA, Morad CS, Yassine EM. Plasma soluble urokinase plasminogen activator receptor levels in systemic lupus erythematosus patients. Egypt J Immunol. 2018;25(1):35-43. [PubMed: 30242996].
-
67.
Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61-74. doi: 10.1016/S0140-6736(18)30536-1. [PubMed: 29910038].
-
68.
Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12(2):332-45. doi: 10.2215/CJN.05000516. [PubMed: 27940460]. [PubMed Central: PMC5293332].
-
69.
Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629-39. doi: 10.1016/S0140-6736(03)14184-0. [PubMed: 12944064].
-
70.
Trivedi M, Pasari A, Chowdhury AR, Abraham-Kurien A, Pandey R. The spectrum of focal segmental glomerulosclerosis from eastern India: Is it different? Indian J Nephrol. 2018;28(3):215-9. doi: 10.4103/ijn.IJN_115_17. [PubMed: 29962672]. [PubMed Central: PMC5998723].
-
71.
Widiasta A, Sribudiani Y, Nugrahapraja H, Hilmanto D, Sekarwana N, Rachmadi D. Potential role of ACE2-related microRNAs in COVID-19-associated nephropathy. Noncoding RNA Res. 2020;5(4):153-66. doi: 10.1016/j.ncrna.2020.09.001. [PubMed: 32923747]. [PubMed Central: PMC7480227].
-
72.
Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science. 2006;311(5761):656-9. doi: 10.1126/science.1121143. [PubMed: 16456079].
-
73.
Campbell KN, Tumlin JA. Protecting podocytes: A key target for therapy of focal segmental glomerulosclerosis. Am J Nephrol. 2018;47 Suppl 1:14-29. doi: 10.1159/000481634. [PubMed: 29852493]. [PubMed Central: PMC6589822].
-
74.
Kronbichler A, Saleem MA, Meijers B, Shin JI. Soluble urokinase receptors in focal segmental glomerulosclerosis: A review on the scientific point of view. J Immunol Res. 2016;2016:2068691. doi: 10.1155/2016/2068691. [PubMed: 27504461]. [PubMed Central: PMC4967695].
-
75.
Gee HY, Zhang F, Ashraf S, Kohl S, Sadowski CE, Vega-Warner V, et al. KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. J Clin Invest. 2015;125(6):2375-84. doi: 10.1172/JCI79504. [PubMed: 25961457]. [PubMed Central: PMC4497755].
-
76.
Lennon R, Watson L, Webb NJA. Nephrotic syndrome in children. Paediatr Child Health. 2010;20(1):36-42. doi: 10.1016/j.paed.2009.10.001.
-
77.
Hoefele J, Beck BB, Weber LT, Brinkkötter P. Steroid-resistentes nephrotisches syndrom. Medizinische Genetik. 2018;30(4):410-21. doi: 10.1007/s11825-018-0215-1.
LEAVE A COMMENT HERE: